In yesterday’s Wall Street session, Illumina Inc. (NASDAQ:ILMN) shares traded at $188.50, up 0.54% from the previous session.
22 analysts cover Illumina Inc. (NASDAQ:ILMN), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $336.00 and a low of $140.00, we find $232.50. Given the previous closing price of $187.49, this indicates a potential upside of 24.01 percent. ILMN stock price is now -7.10% away from the 50-day moving average and -10.02% away from the 200-day moving average. The market capitalization of the company currently stands at $29.64B.
The stock has received a hold rating from 9 analysts and a buy rating from 8. Brokers who have rated the stock have averaged $238.13 as their price target over the next twelve months.
In other news, TOUSI SUSAN H, SVP, Chief Commercial Officer sold 500 shares of the company’s stock on Jun 22. The stock was sold for $100,000 at an average price of $200.00. Upon completion of the transaction, the SVP, Chief Commercial Officer now directly owns 46,522 shares in the company, valued at $8.77 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 01, SVP, Chief People Officer Hoyt Aimee L sold 3,917 shares of the business’s stock. A total of $779,737 was realized by selling the stock at an average price of $199.06. This leaves the insider owning 2,881 shares of the company worth $0.54 million. Insiders disposed of 54,396 shares of company stock worth roughly $10.25 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ILMN stock. A new stake in Illumina Inc. shares was purchased by NOMURA HOLDINGS INC during the first quarter worth $101,456,000. ICAHN CARL C invested $80,892,000 in shares of ILMN during the first quarter. In the first quarter, HOLOCENE ADVISORS, LP acquired a new stake in Illumina Inc. valued at approximately $72,866,000. DUQUESNE FAMILY OFFICE LLC acquired a new stake in ILMN for approximately $20,559,000. CLOUGH CAPITAL PARTNERS L P purchased a new stake in ILMN valued at around $13,603,000 in the second quarter. In total, there are 1,403 active investors with 91.10% ownership of the company’s stock.
On Monday morning Illumina Inc. (NASDAQ: ILMN) stock kicked off with the opening price of $187.59. During the past 12 months, Illumina Inc. has had a low of $173.45 and a high of $248.87. As of last week, the company has a debt-to-equity ratio of 0.33, a current ratio of 1.40, and a quick ratio of 1.20. The fifty day moving average price for ILMN is $202.90 and a two-hundred day moving average price translates $209.48 for the stock.
The latest earnings results from Illumina Inc. (NASDAQ: ILMN) was released for Apr, 2023. According to the Diagnostics & Research Company, earnings per share came in at $0.08, beating analysts’ expectations of $0.02 by 0.06. This compares to $0.54 EPS in the same period last year. The company reported revenue of $1.09 billion for the quarter, compared to $1.22 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -11.12 percent. For the current quarter, analysts expect ILMN to generate $1.17B in revenue.
Illumina Inc.(ILMN) Company Profile
Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; and whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Further, it provides whole-genome sequencing, genotyping, NIPT, and product support services; and Galleri, a multi-cancer early detection test. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. Further, it markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.
